No profile data available.
Camp4 Therapeutics Corp (CAMP) is a healthcare company in the metabolic process treatment drugs industry, based in Cambridge, United States, with about 55 full-time employees.
It reported revenue of $3.50 million for fiscal year 2025, up 436.5% from fiscal year 2024, and net income of -$80.40 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $1.78 million, up 18.8% from a year before. Its largest business segment, Software & Subscription Services, brought in 63% of segment revenue in fiscal year 2023; United States was the largest region with 63%. Its market capitalization was $158.93 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders.
Camp4 Therapeutics reported $3.50 million in revenue for fiscal year 2025, up 436.5% from $652,000 in fiscal year 2024. In Q2 2026 revenue was $1.78 million.
Software & Subscription Services, with $184.73 million or 63% of segment revenue in fiscal year 2023. Next: Telematics Products (37%).
United States: 63% of revenue by region in fiscal year 2023, followed by Europe, Middle East and Africa (19%).
$158.93 million as of December 4, 2025.
Listed companies of a similar size in the same industry (metabolic process treatment drugs) include Amarin Corporation plc (AMRN), Protalix BioTherapeutics, Inc. (PLX), Cartesian Therapeutics, Inc. (RNAC), Xortx Therapeutics Inc. (XRTX).